Cerebral Computed Tomography-Graded White Matter Lesions Are Associated with Worse Outcome after Thrombolysis in Patients with Stroke

Stroke

Volumn 46, Issue 6, 2015, Pages 1554-1560

  Curtze, Sami ^a   Melkas, Susanna ^a   Sibolt, Gerli ^a   Haapaniemi, Elena ^a   Mustanoja, Satu ^a   Putaala, Jukka ^a   Sairanen, Tiina ^a   Tiainen, Marjaana ^a   Tatlisumak, Turgut ^a   Strbian, Daniel ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

outcome measures; thrombolytic therapy

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANKIN SCALE; RATING SCALE; VERY ELDERLY; WHITE MATTER LESION; ADVERSE EFFECTS; BIOLOGICAL MODEL; BRAIN ANGIOGRAPHY; CLINICAL TRIAL; LEUKOENCEPHALOPATHIES; PREDICTIVE VALUE; RADIOGRAPHY; STROKE; VASCULARIZATION; WHITE MATTER;

AGED; AGED, 80 AND OVER; CEREBRAL ANGIOGRAPHY; FEMALE; HUMANS; LEUKOENCEPHALOPATHIES; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; STROKE; THROMBOLYTIC THERAPY; TOMOGRAPHY, X-RAY COMPUTED; WHITE MATTER;

EID: 84938533328     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.008941     Document Type: Article

References (34)

1. Hachinski VC, Potter P, Merskey H. Leuko-araiosis. Arch Neurol. 1987;44:21-23.
2. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al; STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12:822-838. doi: 10.1016/S1474-4422(13)70124-8.
3. Mustanoja S, Meretoja A, Putaala J, Viitanen V, Curtze S, Atula S, et al; Helsinki Stroke Thrombolysis Registry Group. Outcome by stroke etiology in patients receiving thrombolytic treatment: descriptive subtype analysis. Stroke. 2011;42:102-106. doi: 10.1161/STROKEAHA.110.597534.
4. Pantoni L, Fierini F, Poggesi A. Thrombolysis in acute stroke patients with cerebral small vessel disease. Cerebrovasc Dis. 2014;37:5-13. doi:10.1159/000356796.
5. Oksala NK, Oksala A, Pohjasvaara T, Vataja R, Kaste M, Karhunen PJ, et al. Age related white matter changes predict stroke death in long term follow-up. J Neurol Neurosurg Psychiatry. 2009;80:762-766. doi:10.1136/jnnp.2008.154104.
6. Inzitari D, Pracucci G, Poggesi A, Carlucci G, Barkhof F, Chabriat H, et al; LADIS Study Group. Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort. BMJ. 2009;339:b2477.
7. Sibolt G, Curtze S, Melkas S, Pohjasvaara T, Kaste M, Karhunen PJ, et al. White matter lesions are associated with hospital admissions because of hip-fractures and trauma after ischemic stroke. Stroke. 2014;45:2948-2951. doi: 10.1161/STROKEAHA.114.006116.
8. Smith EE. Leukoaraiosis and stroke. Stroke. 2010;41(10 suppl):S139-S143. doi: 10.1161/STROKEAHA.110.596056.
9. Arsava EM, Rahman R, Rosand J, Lu J, Smith EE, Rost NS, et al. Severity of leukoaraiosis correlates with clinical outcome after ischemic stroke. Neurology. 2009;72:1403-1410. doi: 10.1212/WNL.0b013e3181a18823.
10. Fu JH, Chen YK, Chen XY, Mok V, Wong KS. Coexisting small vessel disease predicts poor long-term outcome in stroke patients with intracranial large artery atherosclerosis. Cerebrovasc Dis. 2010;30:433-439. doi: 10.1159/000319574.
11. Henninger N, Lin E, Baker SP, Wakhloo AK, Takhtani D, Moonis M. Leukoaraiosis predicts poor 90-day outcome after acute large cerebral artery occlusion. Cerebrovasc Dis. 2012;33:525-531. doi:10.1159/000337335.
12. Choi JH, Bae HJ, Cha JK. Leukoaraiosis on magnetic resonance imaging is related to long-term poor functional outcome after thrombolysis in acute ischemic stroke. J Korean Neurosurg Soc. 2011;50:75-80. doi:10.3340/jkns.2011.50.2.75.
13. Demchuk AM, Khan F, Hill MD, Barber PA, Silver B, Patel S, et al; NINDS rt-PA Stroke Study Group. Importance of leukoaraiosis on CT for tissue plasminogen activator decision making: evaluation of the NINDS rt-PA Stroke Study. Cerebrovasc Dis. 2008;26:120-125. doi:10.1159/000139658.
14. Ariës MJ, Uyttenboogaart M, Vroomen PC, De Keyser J, Luijckx GJ. tPA treatment for acute ischaemic stroke in patients with leukoaraiosis. Eur J Neurol. 2010;17:866-870. doi: 10.1111/j.1468-1331.2010.02963.x.
15. Palumbo V, Boulanger JM, Hill MD, Inzitari D, Buchan AM; CASES Investigators. Leukoaraiosis and intracerebral hemorrhage after thrombolysis in acute stroke. Neurology. 2007;68:1020-1024. doi: 10.1212/01. wnl.0000257817.29883.48.
16. Meretoja A, Putaala J, Tatlisumak T, Atula S, Artto V, Curtze S, et al. Off-label thrombolysis is not associated with poor outcome in patients with stroke. Stroke. 2010;41:1450-1458. doi: 10.1161/STROKEAHA.109.576140.
17. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604-607.
18. Strbian D, Engelter S, Michel P, Meretoja A, Sekoranja L, Ahlhelm FJ, et al. Symptomatic intracranial hemorrhage after stroke thrombolysis: the SEDAN score. Ann Neurol. 2012;71:634-641. doi: 10.1002/ana.23546.
19. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245-1251.
20. Rezek DL, Morris JC, Fulling KH, Gado MH. Periventricular white matter lucencies in senile dementia of the Alzheimer type and in normal aging. Neurology. 1987;37:1365-1368.
21. Gorter JW. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. Neurology. 1999;53:1319-1327.
22. van Swieten JC, Hijdra A, Koudstaal PJ, van Gijn J. Grading white matter lesions on CT and MRI: a simple scale. J Neurol Neurosurg Psychiatry. 1990;53:1080-1083.
23. Blennow K, Wallin A, Uhlemann C, Gottfries CG. White-matter lesions on CT in Alzheimer patients: relation to clinical symptomatology and vascular factors. Acta Neurol Scand. 1991;83:187-193.
24. Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjögren M, et al; European Task Force on Age-Related White Matter Changes. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32:1318-1322.
25. Optimising Analysis of Stroke Trials (OAST) Collaboration; Bath PMW, Gray LJ, Collier T, Pocock S, Carpenter J. Can we improve the statistical analysis of stroke trials Statistical reanalysis of functional outcomes in stroke trials. Stroke. 2007;38:1911-1915.
26. Strbian D, Meretoja A, Ahlhelm FJ, Pitkäniemi J, Lyrer P, Kaste M, et al. Predicting outcome of IV thrombolysis-treated ischemic stroke patients: the DRAGON score. Neurology. 2012;78:427-432. doi: 10.1212/WNL.0b013e318245d2a9.
27. Kapeller P, Barber R, Vermeulen RJ, Adèr H, Scheltens P, Freidl W, et al; European Task Force of Age Related White Matter Changes. Visual rating of age-related white matter changes on magnetic resonance imaging: scale comparison, interrater agreement, and correlations with quantitative measurements. Stroke. 2003;34:441-445.
28. Strbian D, Seiffge DJ, Breuer L, Numminen H, Michel P, Meretoja A, et al. Validation of the DRAGON score in 12 stroke centers in anterior and posterior circulation. Stroke. 2013;44:2718-2721. doi: 10.1161/STROKEAHA.113.002033.
29. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2010;341:c3666.
30. Sibolt G, Curtze S, Melkas S, Pohjasvaara T, Kaste M, Karhunen PJ, et al. Post-stroke depression and depression-executive dysfunction syndrome are associated with recurrence of ischaemic stroke. Cerebrovasc Dis. 2013;36:336-343. doi: 10.1159/000355145.
31. Melkas S, Sibolt G, Oksala NK, Putaala J, Pohjasvaara T, Kaste M, et al. Extensive white matter changes predict stroke recurrence up to 5 years after a first-ever ischemic stroke. Cerebrovasc Dis. 2012;34:191-198. doi: 10.1159/000341404.
32. Henninger N, Lin E, Haussen DC, Lehman LL, Takhtani D, Selim M, et al. Leukoaraiosis and sex predict the hyperacute ischemic core volume. Stroke. 2013;44:61-67. doi: 10.1161/STROKEAHA.112.679084.
33. Henninger N, Khan MA, Zhang J, Moonis M, Goddeau RP Jr. Leukoaraiosis predicts cortical infarct volume after distal middle cerebral artery occlusion. Stroke. 2014;45:689-695. doi: 10.1161/STROKEAHA.113.002855.
34. Zhang J, Puri AS, Khan MA, Goddeau RP Jr, Henninger N. Leukoaraiosis predicts a poor 90-day outcome after endovascular stroke therapy. AJNR Am J Neuroradiol. 2014;35:2070-2075. doi: 10.3174/ajnr.A4029.